At a glance
ClinicalIndex Comparison RecordN/ACompleted· 12,551 enrolled
Drug / intervention
rt-PAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
1-year Clinical Outcomes After Intravenous Rt-PA for Chinese AIS Patients
In Brief
An observational study evaluating rt-PA for Stroke. Completed, enrolled 12,551 participants across 1 site.
Detailed Summary
The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of symptom onset compared with those who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive any reperfusion treatment in a real-world clinical setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsStroke
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartApr 2022
First PostedMay 2022
Primary CompletionNov 2022
TodayJul 2026
First PostedMay 27, 2022
Enrollment StartApr 12, 2022
Primary CompletionNov 30, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.1 years ago
Interventions
rt-PAdrug
Recombinant Tissue Plasminogen Activator